FDA approvals are critical milestones for pharmaceutical companies, often leading to increased stock prices due to the potential for significant revenue growth. The approval of INGREZZA Sprinkle capsules is directly related to Neurocrine Biosciences' core business, making this news highly relevant and important for investors. The positive impact on the stock price is expected to be short-term as the market reacts to the news, but the long-term effects will depend on the commercial success of the product.